Avanir Pharmaceuticals (Nasdaq: AVNR ) is expected to report Q1 earnings around Feb. 3. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Avanir Pharmaceuticals's revenues will increase 129.2% and EPS will remain in the red.
The average estimate for revenue is $16.4 million. On the bottom line, the average EPS estimate is -$0.08.
Last quarter, Avanir Pharmaceuticals recorded revenue of $13.5 million. GAAP reported sales were much higher than the prior-year quarter's $4.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.09. GAAP EPS were -$0.09 for Q4 compared to -$0.14 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 94.7%, 80 basis points worse than the prior-year quarter. Operating margin was -78.9%, 29,890 basis points better than the prior-year quarter. Net margin was -86.6%, 29,120 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $80.2 million. The average EPS estimate is -$0.17.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 186 members out of 250 rating the stock outperform, and 64 members rating it underperform. Among 60 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Avanir Pharmaceuticals a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Avanir Pharmaceuticals is outperform, with an average price target of $5.60.